Clinical role of natrilix SR in the treatment of at-risk hypertensive patients

Journal of Hypertension, Supplement

Volumn 21, Issue 1, 2003, Pages

  Ambrosioni, Ettore ^a   Veronesi, Maddalena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diabetic microalbuminuria; Elderly; Hypertension treatment; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLUCOSE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LIPID; PLACEBO; POTASSIUM;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FUNCTION; MICROALBUMINURIA; MORBIDITY; MORTALITY; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SLOW RELEASE FORMULATION; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

DELAYED-ACTION PREPARATIONS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INDAPAMIDE; RISK FACTORS; TREATMENT OUTCOME;

EID: 0038745927     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
2. Mancia G, Grassi G. Rationale for the use of a fixed combination in the treatment of hypertension. Eur Heart J Supplements 1999; 1(Suppl L): L14-L19.
3. Guidelines subcommittee. 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
4. Kaplan NM. Diuretics as a basis of antihypertensive therapy. An overview. Drugs 2000; 59(Suppl 2):21-25.
5. Leonetti G, Rappelli A, Salvetti A, Scalpellato L. Long-term effects of indapamide: final results of 2-year Italian multicenter study in systemic hypertension. Am J Cardiol 1990; 65:67H-71H.
6. Chaffman M, Hell RC, Brodgen RN, Speight TM, Avery GS. Indapamide: a review of its pharmacodynamic proprieties and therapeutic efficacy in hypertension. Drugs 1988; 28:12-249.
7. Guez D, Mallion JM, Degaute JP, Malini PL, Baldwin R, Rodriguez-Pujol D, et al. Treatment of hypertension with indapamide 1.5 mg sustained-release form: synthesis of results [in French]. Arch Mal Coeur Vaiss 1996; 89:17-25.
8. Mallion JM, Asmar R, Ambrosioni E, MacMahon M, Coupez JM, de Cordoüe A, et al. Evaluation du rapport vallée/pic de l'indapamide 1.5 mg comprimé enrobé à libération prolongée par la mesure ambulatoire de la pression artérielle. Arch Mal Coeur Vaiss 1996; 89:27-38.
9. Ambrosioni E, Safar M, Degaute J-P, Malini PG, MacMahon M, Rodriguez-Pujol D, et al., on behalf of the European study group. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998; 16:1677-1684.
10. Donnelly R. Clinical implications of indapamide sustained release 1.5 mg in hypertension. Clin Pharmacokinet 1999; 37(Suppl 1):21-32.
11. Emeriau JP, Knauf H, Pujadas JO, Calvo-Gomez C, Abate G, Leonetti G, et al., on behalf of the European Study Investigators. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001; 19:343-350.
12. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickening TG, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbidity events in hypertensive men. Ann Intern Med 1986; 105:173-178.
13. Dahlof B, Pennert K, Hansson L. Regression of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies Am J Hypertens 1992; 5:95-110.
14. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial change in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
15. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997; 95:1983-1985.
16. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al., on behalf of the LIVE investigators. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18:1465-1475.
17. Gosse P, Dubourg O, Gueret P. Influence of left ventricular pattern in left ventricular hypertrophy changes after 1 year of treatment in the LIVE study. J Hypertens 2000; 18(Suppl 4):S58.
18. Leonetti G, Emeriau JP, Knauf H, Pujadas JO, Calvo-Gomez C. Evaluation of long-term efficacy of indapamide SR 1.5 mg in elderly hypertensive patients. Am J Hypertens 2001; 14(4 Part 2):102A-103A.
19. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, et al. Hypertension in the very elderly trial (HYVET). Drugs Aging 2001; 18(3):151-164.
20. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310:356-360.
21. Steigler H, Standl E, Schultz K, Roth R, Lehmacher W. Morbidity, mortality, and albuminuria in type 2 diabetic patients: a three-year prospective study of a random cohort in general practice. Diabetic Med 1992; 9:646-653.
22. Molyneaux LM, Willey KA, Yue DK. Indapamide is as effective as captopril in the control of microalbuminuria in diabetes. J Cardiovasc Pharmacol 1996; 27:424-427.
23. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25(Suppl 1):S71-S73.
24. Marre M. Indapamide SR 1.5 mg versus enalapril in the regression of microalbuminuria in hypertensive type II diabetic patients. J Hypertens 1998; 16:S334.
25. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Data from three randomised double-blind studies. Drug Safety 2001; 24:1155-1165.